Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

| 01 September 2011 | By Beatriz RochaHeddie MartynowiczRolW. UsherAndrew FriedmanJonathon ParkerRichard FanelliSuzanne Thornton-JonesCynthia AronsMark Ammann 

The US Food and Drug Administration (FDA) is collaborating with private and public stakeholders in an effort to address critical public health needs and to bridge scientific gaps.1 One of these collaborations focuses on abuse potential and involves three key groups: the Controlled Substance Staff (CSS) of FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Cross Company Abuse Liability Consortium (CCALC).


© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy